2025
Positron Emission Tomography Radiotracers for Identification of Site of Recurrence in Prostate Cancer After Primary Treatment Failure
Bitar R, Zurita P, Martiniova L, Zurita A, Ravizzini G. Positron Emission Tomography Radiotracers for Identification of Site of Recurrence in Prostate Cancer After Primary Treatment Failure. Cancers 2025, 17: 1723. PMID: 40427220, PMCID: PMC12109795, DOI: 10.3390/cancers17101723.Peer-Reviewed Original ResearchProstate-specific membrane antigenProstate-specific antigenProstate cancerPositron emission tomographyPositron emission tomography radiotracersBiochemical recurrenceF-FDGUpregulation of amino acid transportersProstate-specific membrane antigen expressionBiochemical recurrence of prostate cancerInvestigate positron emission tomographySerum prostate-specific antigenRecurrence of prostate cancerPrimary treatment failurePSMA-targeted agentsSite of recurrencePrimary prostate cancerSalvage therapyF-fluciclovineLocalized diseaseTreatment failureDefinitive managementMembrane antigenInvestigational agentsRadionuclide therapy
2024
Small Cell Bladder Cancer: Treatment Patterns for Local Disease and Associated Outcomes. A Retrospective Cohort Study
Bakaloudi D, Koehne E, Diamantopoulos L, Holt S, Sekar R, Ghali F, Vakar-Lopez F, Nyame Y, Psutka S, Gore J, de la Calle C, Lin D, Schade G, Liao J, Hsieh A, Yezefski T, Hawley J, Yu E, Montgomery R, Grivas P, Wright J. Small Cell Bladder Cancer: Treatment Patterns for Local Disease and Associated Outcomes. A Retrospective Cohort Study. Clinical Genitourinary Cancer 2024, 22: 102208. PMID: 39265260, DOI: 10.1016/j.clgc.2024.102208.Peer-Reviewed Original ResearchSmall cell bladder cancerConcurrent chemoradiotherapyNeoadjuvant chemotherapySEER-Medicare databaseMedian OSLocoregional therapySEER-MedicareBladder cancerHistological subtypesOverall survivalInstitutional databaseCompare outcomesOptimal locoregional therapyAggressive histologic subtypeNon-metastatic stageNon-metastatic diseaseSEER-Medicare datasetMultivariate Cox analysisFollow-up/deathLocalized diseaseCox analysisCystectomyTreatment patternsTreatment responseMultivariate analysisRisk factors for Gleason score upgrade from prostate biopsy to radical prostatectomy
Smani S, Sundaresan V, Lokeshwar S, Choksi A, Carbonella J, Brito J, Renzulli J, Sprenkle P, Leapman M. Risk factors for Gleason score upgrade from prostate biopsy to radical prostatectomy. Exploration Of Targeted Anti-tumor Therapy 2024, 5: 981-996. PMID: 39280242, PMCID: PMC11390291, DOI: 10.37349/etat.2024.00259.Peer-Reviewed Original ResearchGleason score upgradingProstate-specific antigenRisk factorsMagnetic resonance imagingRadical prostatectomyScore upgradingAssociated with Gleason score upgradingBiopsy to radical prostatectomyHigher-risk prostate cancerPatients treated with surgeryProstate magnetic resonance imagingClinically localized diseaseGleason grade groupLow-risk diseaseRecognition of risk factorsBody mass indexGleason upgradingFinal pathologyProstate volumeProstate biopsySource of diagnostic uncertaintyBiopsy coresLocalized diseaseProstate cancerInitial managementEarly-onset appendiceal adenocarcinoma (EOAA): 10-year experience from a single center.
Gujarathi R, Belmont E, Rodman C, Bansal V, Setia N, Alpert L, Hart J, Moller M, Eng O, Lee G, Chin J, Amin M, Polite B, Liao C, Turaga K, Shergill A. Early-onset appendiceal adenocarcinoma (EOAA): 10-year experience from a single center. Journal Of Clinical Oncology 2024, 42: 4178-4178. DOI: 10.1200/jco.2024.42.16_suppl.4178.Peer-Reviewed Original ResearchOutcomes of overall survivalAppendiceal adenocarcinomaEarly-onset diseasePerineural invasionCytoreductive surgeryUnivariate Cox proportional hazards regression analysisCox proportional hazards regression analysisIncidence of early-onsetAssociated with poor outcomesGrade 3 diseaseProportional hazards regression analysisTargetable genomic alterationsHigh-volume centersLymph node metastasisRecords of patientsHazards regression analysisGermline mutation testingLate-onset diseaseCHEK2 mutationsMedian OSVulnerable patient populationCancer ptsOverall survivalLocalized diseaseMetastatic/recurrent disease
2023
Relative Burden of Cancer and Noncancer Mortality Among Long-Term Survivors of Breast, Prostate, and Colorectal Cancer in the US
Kc M, Fan J, Hyslop T, Hassan S, Cecchini M, Wang S, Silber A, Leapman M, Leeds I, Wheeler S, Spees L, Gross C, Lustberg M, Greenup R, Justice A, Oeffinger K, Dinan M. Relative Burden of Cancer and Noncancer Mortality Among Long-Term Survivors of Breast, Prostate, and Colorectal Cancer in the US. JAMA Network Open 2023, 6: e2323115. PMID: 37436746, PMCID: PMC10339147, DOI: 10.1001/jamanetworkopen.2023.23115.Peer-Reviewed Original ResearchConceptsLong-term survivorsCancer-specific mortalityColorectal cancerCancer cohortReceptor statusInitial diagnosisGleason scoreProstate cancerBreast cancerLong-term adult survivorsMedian cancer-specific survivalEnd Results cancer registryProstate-specific antigen levelRectal cancer cohortCancer-specific survivalStage III diseaseYear of diagnosisProgesterone receptor statusEstrogen receptor statusProportion of deathsSurvival time ratioEarly-stage cancerNononcologic outcomesIndex cancerLocalized diseaseSynthesizing and Applying Molecular Targeted Imaging Results in Patients With Prostate Cancer (RADAR VII)
Crawford E, Harris R, Slovin S, Concepcion R, Albala D, Gomella L, Orio P, Sellinger S, Petrylak D, Koo P. Synthesizing and Applying Molecular Targeted Imaging Results in Patients With Prostate Cancer (RADAR VII). JU Open Plus 2023, 1 DOI: 10.1097/ju9.00000000000000011.Peer-Reviewed Original ResearchProstate cancerNonmetastatic castrate-resistant prostate cancerClinical decisionCastrate-resistant prostate cancerConventional imagingLimited clinical dataTreatment of patientsFuture clinical trialsTreatment decision makingProstate cancer researchLimited available evidenceNuclear medicine specialistsLocalized diseaseMetastatic diseaseMedical oncologistsProspective studyBiochemical recurrenceClinical trialsRadiographic assessmentClinical dataMore robust recommendationsMedicine specialistsClinical experienceConsensus guidanceRadiation oncologists
2021
Evaluation of Insurance Coverage and Cancer Stage at Diagnosis Among Low-Income Adults With Renal Cell Carcinoma After Passage of the Patient Protection and Affordable Care Act
Javier-DesLoges JF, Yuan J, Soliman S, Hakimi K, Meagher MF, Ghali F, Hsiang W, Patel DN, Kim SP, Murphy JD, Parsons JK, Derweesh IH. Evaluation of Insurance Coverage and Cancer Stage at Diagnosis Among Low-Income Adults With Renal Cell Carcinoma After Passage of the Patient Protection and Affordable Care Act. JAMA Network Open 2021, 4: e2116267. PMID: 34269808, PMCID: PMC8285737, DOI: 10.1001/jamanetworkopen.2021.16267.Peer-Reviewed Original ResearchConceptsLow-income patientsRenal cell carcinomaAffordable Care ActACA implementationNonexpansion statesLocalized diseaseAbsolute percentage changeCell carcinomaCancer stageExpansion statesNational Cancer DatabaseProportion of patientsRetrospective cohort analysisInsurance coveragePatient ProtectionCare ActMedicaid expansion statesInsurance coverage statusLow-income adultsEarly RCC detectionExpansion of insuranceSecondary outcomesInsurance statusAdjusted differenceCancer DatabaseBarriers and facilitators of germline genetic evaluation for prostate cancer.
Loeb S, Li R, Sanchez Nolasco T, Byrne N, Cheng H, Leader A, Giri V. Barriers and facilitators of germline genetic evaluation for prostate cancer. Journal Of Clinical Oncology 2021, 39: 28-28. DOI: 10.1200/jco.2021.39.6_suppl.28.Peer-Reviewed Original ResearchCoordination of careProstate cancerGenetic testingChronic Diseases frameworkGuideline-concordant careGermline genetic testingMetastatic prostate cancerGenetic counselingGermline testingLocalized diseasePatient factorsMedical oncologistsTherapeutic optionsCancer screeningPhysicians' knowledgeCurrent guidelinesPhysician educationRecent approvalRadiation oncologistsPractice settingsCancerDisease frameworkThematic saturationProstate Cancer GeneticsGenetic evaluation
2020
Clinical Implications of Germline Testing in Newly Diagnosed Prostate Cancer
Loeb S, Giri V. Clinical Implications of Germline Testing in Newly Diagnosed Prostate Cancer. European Urology Oncology 2020, 4: 1-9. PMID: 33390340, DOI: 10.1016/j.euo.2020.11.011.Peer-Reviewed Reviews, Practice Guidelines, Standards, and Consensus StatementsConceptsGermline testingLocalized diseaseMetastatic PCaFamily historyGermline evaluationMetastatic diseaseCurrent guidelinesProstate cancerCancer riskPractice settingsGenetic testingDNA mismatch repair deficiencyManagement of menProstate cancer managementFamily cancer riskEarly-stage PCaMismatch repair deficiencyHereditary cancer riskPathologic featuresHistologic featuresMedical oncologyCancer screeningPCa managementPCa riskConsensus panelPredicting prostate cancer death among 98,994 veterans: Differences by race/ethnicity.
Janet T, Danciu I, Justice A, Leapman M, McMahon B, Wadia R. Predicting prostate cancer death among 98,994 veterans: Differences by race/ethnicity. Journal Of Clinical Oncology 2020, 38: e17609-e17609. DOI: 10.1200/jco.2020.38.15_suppl.e17609.Peer-Reviewed Original ResearchProstate cancer deathNon-Hispanic blacksNon-Hispanic whitesVeterans Affairs Healthcare SystemRace/ethnicityHazard ratioGleason scoreCancer deathProstate cancerU.S. Veterans Affairs healthcare systemProstate cancer disease progressionDistant metastatic diseaseProstate cancer mortalityCancer disease progressionLocalized diseasePSA levelsMedian ageMetastatic diseaseLymph nodesPrognostic indexCancer mortalityTumor stageDisease progressionCox modelAge strataGeographic-Level Association of Contemporary Changes in Localized and Metastatic Prostate Cancer Incidence in the Era of Decreasing PSA Screening
Yang DX, Makarov DV, Gross CP, Yu JB. Geographic-Level Association of Contemporary Changes in Localized and Metastatic Prostate Cancer Incidence in the Era of Decreasing PSA Screening. Cancer Control 2020, 27: 1073274820902267. PMID: 32003227, PMCID: PMC7003204, DOI: 10.1177/1073274820902267.Peer-Reviewed Original ResearchConceptsMetastatic prostate cancer incidenceProstate cancer incidenceHealth care service areasMetastatic diseaseCancer incidenceNational Cancer Institute's SurveillanceEnd Results (SEER) databaseLocalized prostate cancerSEER 18 registriesProstate-specific antigenPSA screeningLocalized diseaseResults databaseProstate cancerOlder menMetastatic incidenceIncidenceDiseaseDiagnosisLate changesMenRecent increaseAssociationRegistryCancerBreast cancer induces systemic immune changes on cytokine signaling in peripheral blood monocytes and lymphocytes
Wang L, Simons D, Lu X, Tu T, Avalos C, Chang A, Dirbas F, Yim J, Waisman J, Lee P. Breast cancer induces systemic immune changes on cytokine signaling in peripheral blood monocytes and lymphocytes. EBioMedicine 2020, 52: 102631. PMID: 31981982, PMCID: PMC6992943, DOI: 10.1016/j.ebiom.2020.102631.Peer-Reviewed Original ResearchConceptsSystemic immune changesPeripheral blood monocytesBreast Cancer Research FoundationBreast Cancer Research ProgramBC patientsImmune changesBlood monocytesPeripheral bloodImmune cellsNon-metastatic BC patientsPeripheral blood immune cellsPeripheral blood T cellsCancer patients' peripheral bloodBlood immune cellsBreast cancer patientsOverall immune statusBlood T cellsPatients' peripheral bloodTumor-infiltrating macrophagesDefense Breast Cancer Research ProgramCancer Research ProgramCancer Research FoundationConcurrent cytokineLocalized diseaseImmune status
2019
Multiplex plasma protein profiling identifies novel markers to discriminate patients with adenocarcinoma of the lung
Djureinovic D, Pontén V, Landelius P, Al Sayegh S, Kappert K, Kamali-Moghaddam M, Micke P, Ståhle E. Multiplex plasma protein profiling identifies novel markers to discriminate patients with adenocarcinoma of the lung. BMC Cancer 2019, 19: 741. PMID: 31357969, PMCID: PMC6664554, DOI: 10.1186/s12885-019-5943-3.Peer-Reviewed Original ResearchMeSH KeywordsAdenocarcinoma of LungAgedBlood ProteinsCarcinoembryonic AntigenCarcinoma, Non-Small-Cell LungChemokines, CXCCohort StudiesData AccuracyEarly Detection of CancerFemaleGPI-Linked ProteinsHumansImmunoassayLung NeoplasmsMaleMass ScreeningModels, BiologicalReceptor, ErbB-3ROC CurveSensitivity and SpecificityStatistics, NonparametricVascular Endothelial Growth Factor Receptor-2ConceptsNon-small cell lung cancerProximity extension assayLung adenocarcinomaLung diseaseDisease groupNon-malignant lung diseasesEarly lung cancer detectionCell lung cancerDifferent lung diseasesDifferent plasma levelsMultiplex proximity extension assayHigh clinical relevanceNovel protein markersDifferent plasma concentrationsLocalized diseaseOverall prognosisSurgical resectionNSCLC patientsLung metastasesColorectal cancerLung cancerPlasma levelsTypical carcinoidLung conditionsLAC patientsContemporary changes in localized and metastatic prostate cancer incidence by geographic area following decreased PSA screening.
Yang D, Makarov D, Gross C, Yu J. Contemporary changes in localized and metastatic prostate cancer incidence by geographic area following decreased PSA screening. Journal Of Clinical Oncology 2019, 37: 1567-1567. DOI: 10.1200/jco.2019.37.15_suppl.1567.Peer-Reviewed Original ResearchProstate cancer incidenceHealth service areasMetastatic prostate cancerMetastatic prostate cancer incidenceMetastatic diseaseCancer incidenceProstate cancerLocalized diseasePopulation-weighted linear regressionMen 70 yearsEnd Results (SEER) databaseHealth Service regionResults databaseIncidence rateHospital careMetastatic incidenceIncidenceDiseaseCancerLate increasePSALinear regressionMenTemporal relationshipSurveillanceProstate Cancer, Version 2.2019, NCCN Clinical Practice Guidelines in Oncology.
Mohler J, Antonarakis E, Armstrong A, D'Amico A, Davis B, Dorff T, Eastham J, Enke C, Farrington T, Higano C, Horwitz E, Hurwitz M, Ippolito J, Kane C, Kuettel M, Lang J, McKenney J, Netto G, Penson D, Plimack E, Pow-Sang J, Pugh T, Richey S, Roach M, Rosenfeld S, Schaeffer E, Shabsigh A, Small E, Spratt D, Srinivas S, Tward J, Shead D, Freedman-Cass D. Prostate Cancer, Version 2.2019, NCCN Clinical Practice Guidelines in Oncology. Journal Of The National Comprehensive Cancer Network 2019, 17: 479-505. PMID: 31085757, DOI: 10.6004/jnccn.2019.0023.Peer-Reviewed Original ResearchConceptsProstate cancerRisk stratificationNCCN Clinical Practice GuidelinesMultigene molecular testingSecondary hormonal therapyAndrogen deprivation therapySomatic genetic testingClinical practice guidelinesDeprivation therapyHormone therapyLocalized diseaseAdvanced diseaseNCCN guidelinesTreated patientsTreatment optionsMolecular testingProstateGenetic testingCancerTherapyPractice guidelinesPatientsNCCNDiseaseGuidelinesSuicide among cancer patients
Zaorsky NG, Zhang Y, Tuanquin L, Bluethmann SM, Park HS, Chinchilli VM. Suicide among cancer patients. Nature Communications 2019, 10: 207. PMID: 30643135, PMCID: PMC6331593, DOI: 10.1038/s41467-018-08170-1.Peer-Reviewed Original ResearchConceptsStandardized mortality ratioCancer patientsHigh riskHigher standardized mortality ratiosColorectal cancer patientsEnd Results ProgramPopulation-based studyYears of agePredominant patientsLocalized diseasePerson yearsResults ProgramHodgkin's lymphomaTesticular tumorsMortality ratioRates of suicideGeneral populationPatientsCommitted suicideUnmarried malesLungSuicideRiskRepresentative dataLymphoma
2017
Risk of myeloid neoplasms after radiotherapy among older women with localized breast cancer: A population-based study
Zeidan AM, Long JB, Wang R, Hu X, Yu JB, Huntington SF, Abel GA, Mougalian SS, Podoltsev NA, Gore SD, Gross CP, Ma X, Davidoff AJ. Risk of myeloid neoplasms after radiotherapy among older women with localized breast cancer: A population-based study. PLOS ONE 2017, 12: e0184747. PMID: 28902882, PMCID: PMC5597231, DOI: 10.1371/journal.pone.0184747.Peer-Reviewed Original ResearchConceptsBreast cancer survivorsMyeloid neoplasmsCancer survivorsBreast cancerOlder womenOlder breast cancer survivorsTherapy-related myeloid neoplasmsCompeting-risks survival analysisAbsolute risk increaseBenefits of radiotherapyPopulation-based studyAbsence of chemotherapyRisk of developmentMultiple sensitivity analysesEligible patientsSubsequent chemotherapyAdjuvant radiotherapyLocalized diseaseCumulative incidenceInitial treatmentSEER registryPoor outcomeTreatment recommendationsMedicare claimsMN diagnosis
2016
Palliative Care for Pancreatic and Periampullary Cancer
Perone JA, Riall TS, Olino K. Palliative Care for Pancreatic and Periampullary Cancer. 2016, 96: 1415-1430. PMID: 27865285, PMCID: PMC5119929, DOI: 10.1016/j.suc.2016.07.012.Peer-Reviewed Original ResearchConceptsMost patientsPalliative careGastric outlet obstructionRelief of painPancreatic cancer patientsAdvanced diseaseLocalized diseaseMultimodality therapyCeliac plexusOutlet obstructionPeriampullary cancerObstructive jaundiceCancer patientsPancreatic cancerPalliative techniquesPatientsCommon endpointCancerDiseaseReliefCareCare triangleFamily goalsJaundicePainTrends in esophageal cancer survival in United States adults from 1973 to 2009: A SEER database analysis
Njei B, McCarty TR, Birk JW. Trends in esophageal cancer survival in United States adults from 1973 to 2009: A SEER database analysis. Journal Of Gastroenterology And Hepatology 2016, 31: 1141-1146. PMID: 26749521, PMCID: PMC4885788, DOI: 10.1111/jgh.13289.Peer-Reviewed Original ResearchMeSH KeywordsAdenocarcinomaAge FactorsAgedCarcinoma, Squamous CellEarly Detection of CancerEsophageal NeoplasmsEsophageal Squamous Cell CarcinomaEsophagectomyFemaleHumansKaplan-Meier EstimateMaleMiddle AgedMultivariate AnalysisNeoplasm StagingPredictive Value of TestsProportional Hazards ModelsRetrospective StudiesRisk FactorsSEER ProgramSurvival RateTime FactorsTreatment OutcomeUnited StatesConceptsSquamous cell carcinomaEsophageal cancerEsophageal adenocarcinomaMedian survivalBetter long-term survival outcomesLong-term survival outcomesOverall median survivalEnd Results (SEER) databaseProportion of patientsSEER database analysisSignificant survival improvementProportional hazards regressionEsophageal cancer survivalLong-term survivalIndependent mortality factorsLocalized diseaseCurative stageSurgical treatmentSurvival improvementHazards regressionResults databaseSurvival outcomesCell carcinomaTreatment modalitiesCancer survival
2015
Clinical implications of genomic alterations in the tumour and circulation of pancreatic cancer patients
Sausen M, Phallen J, Adleff V, Jones S, Leary R, Barrett M, Anagnostou V, Parpart-Li S, Murphy D, Kay Li Q, Hruban C, Scharpf R, White J, O’Dwyer P, Allen P, Eshleman J, Thompson C, Klimstra D, Linehan D, Maitra A, Hruban R, Diaz L, Von Hoff D, Johansen J, Drebin J, Velculescu V. Clinical implications of genomic alterations in the tumour and circulation of pancreatic cancer patients. Nature Communications 2015, 6: 7686. PMID: 26154128, PMCID: PMC4634573, DOI: 10.1038/ncomms8686.Peer-Reviewed Original ResearchConceptsGenomic alterationsGenetic predictors of outcomeDetect circulating tumor DNAAssociated with improved survivalTumor-specific mutationsPancreatic cancer patientsLiquid biopsy analysisClinical implicationsPredictors of outcomeWhole-exome analysisDetection of ctDNAPotential therapeutic utilityClinical relapseLocalized diseaseTumor DNAPancreatic adenocarcinomaImproved survivalPancreatic cancerSolid cancersTumor typesBiopsy analysisPoor outcomeCancer patientsSomatic mutationsTumor
This site is protected by hCaptcha and its Privacy Policy and Terms of Service apply